On February 18, 2022 Sandoz reported the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) guidelines (Press release, Sandoz, FEB 18, 2022, View Source [SID1234608325]). The medicine will become available to patients in 19 countries across Europe.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud to make life-enhancing cancer treatments more accessible by launching our affordable and effective Sandoz Lenalidomide", said Rebecca Guntern, Head of Sandoz Europe.
She added: "Sandoz is committed to developing and providing generic oncology therapies, to increase patient access to affordable, high-quality medicines. Today, we offer a broad portfolio of more than 50 oncology products3, ranging from biologics to chemotherapeutics, hormones and supportive care treatments, covering a wide range of cancer indications."
The cost of treating multiple myeloma patients is high and continues to rise5. Affordability of and access to new multiple myeloma treatments pose a major challenge around the world6. Cost savings from Lenalidomide Sandoz promise to expand access to treatment options for multiple myeloma patients1,2. Similar to multiple myeloma patients, cost savings from Lenalidomide Sandoz will benefit previously treated follicular lymphoma patients, adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality, and relapsed or refractory mantle cell lymphoma patients1.
Sandoz is the #1 provider of generic oncology medicines in Europe7 with a growing portfolio that covers an industry-leading 75% of molecules on the WHO’s global Oncology Essential Medicines List8,9. Sandoz invests in development to improve the lives of cancer patients and free up healthcare resources through increased access to high-quality, affordable medicines.
About Lenalidomide
Lenalidomide is an oral thalidomide analogue with immunomodulatory, antiangiogenic, and antineoplastic properties used for the treatment of various haemato-oncology conditions [1]. Lenalidomide is recommended by the latest ESMO (Free ESMO Whitepaper) guidelines [4]. It is available only through special distribution program because of its serious side effects, including possible birth defects or death of an unborn baby [1]. Lenalidomide is available as hard capsules and need to be taken exactly as prescribed [1].